1177798-88-7
基本信息
三盐酸BRACO-19
N,N'-[9[[4-(二甲氨基)苯基]氨基]-3,6-吖啶二基]双(1-吡咯烷丙酰胺)三盐酸盐
BRACO19 HCl
BRACO-19 (BRACO19)
BRACO19 trihydrochloride
N,N-[9[[4-(Dimethylamino)phenyl]amino]-3,6-acridinediyl]bis-1-pyrrolidinepropanamide Trihydrochlori
N,N'-[9[[4-(Dimethylamino)phenyl]amino]-3,6-acridinediyl]bis-1-pyrrolidinepropanamide trihydrochloride
N,N′-(9-(4-(Dimethylamino)phenylamino)acridine-3,6-diyl)bis(3-(pyrrolidin-1-yl)propanamide) trihydrochloride
物理化学性质
| 储存条件 | 2-8°C |
| 溶解度 | H2O：可溶5mg/mL，澄清 |
| 形态 | 粉末 |
| 颜色 | 黄色到棕色 |
| 水溶解性 | H2O: 5mg/mL, clear |
安全数据
| 危险性符号(GHS) |  GHS06 |
| 警示词 | 危险 |
| 危险性描述 | H301 |
| 防范说明 | P264-P270-P301+P310-P405-P501 |
| 危险品标志 | T |
| 危险类别码 | 25 |
| 安全说明 | 45 |
| 危险品运输编号 | UN 2811 6.1 / PGIII |
| WGK Germany | 3 |
化合物 T23819价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/05 | HY-15523A | 化合物 T23819 Braco-19 trihydrochloride | 1177798-88-7 | 5 mg | 1400元 |
| 2025/02/05 | HY-15523A | 化合物 T23819 Braco-19 trihydrochloride | 1177798-88-7 | 10 mM * 1 mLin Water | 2166元 |
| 2025/02/05 | HY-15523A | 化合物 T23819 Braco-19 trihydrochloride | 1177798-88-7 | 10 mg | 2300元 |
常见问题列表
IC50: telomerase
Braco-19 trihydrochloride, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication.BRACO-19 trihydrochloride (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC 50 for BRACO-19 in UXF1138L cells is 2.5 μM, the IC 100 is 5 μM.BRACO-19 trihydrochloride (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses.BRACO-19 trihydrochloride (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells.BRACO-19 trihydrochloride (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner.
Cell Viability Assay
| Cell Line: | HEK 293 cells |
| Concentration: | 20 μM; 40 μM |
| Incubation Time: | 24 hours |
| Result: | Displayed low cytotoxicity and decreased the eGFP fluorescence. |
BRACO-19 trihydrochloride (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts. BRACO-19 trihydrochloride (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors).
| Animal Model: | Established UXF1138LX Xenografts in nude mice |
| Dosage: | 2 mg/kg |
| Administration: | Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments |
| Result: | Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control. |